LLY

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2000, for Eli Lilly & Co. The company operates primarily in the pharmaceutical products segment, with a smaller animal health business. The report highlights significant sales growth driven by diabetes care products, Zyprexa, and Evista, while noting ongoing patent litigation regarding Prozac and the impact of generic competition in international markets.

Key Financial Metrics

Note: Total debt calculated as Short-term borrowings ($51.8M) plus Long-term debt ($2,783.1M) for Q1 2000.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 9% year-over-year, driven by a 53% surge in diabetes care revenues and 14% growth in Zyprexa sales. This was partially offset by a 39% decline in Axid sales and a 14% drop in anti-infectives.
• Profitability: Income from continuing operations rose significantly to $845.5 million from $451.4 million. This increase was heavily influenced by a one-time gain of $214.4 million from the sale of the company's interest in Kinetra LLC.
• Excluding Unusual Items: Management notes that excluding unusual items (Kinetra gain, Y2000 wholesaler buying shifts, and prior year charges), adjusted income from continuing operations increased 18% to $692.3 million.
• Prozac Sales: Worldwide Prozac sales increased 1% to $596.2 million. While U.S. sales rose 12%, international sales fell 35% due to generic competition in the U.K.
• Debt Reduction: Total debt decreased by approximately $218.5 million from the prior quarter, primarily due to the repayment of $200 million in euro bonds.

Guidance, Outlook, and Risks

• Outlook: Management expects slight declines in worldwide Prozac sales for 2000 due to generic competition. Conversely, strong growth is anticipated for Actos (diabetes) and Zyprexa (due to a new FDA indication for acute mania). Moderate growth is expected for other diabetes care products.
• Capital Allocation: The company announced a new $3.0 billion share repurchase program in March 2000. Management believes operating cash flow and existing cash reserves are sufficient to fund operations, debt service, and dividends.
• Legal Risks (Prozac Patents): Multiple generic manufacturers (Barr, Geneva, Teva, Zenith, Cheminor, Alphapharm) have filed Abbreviated New Drug Applications (ANDAs) challenging the validity of Prozac patents expiring in 2001 and 2003. While the company has won partial summary judgments, appeals are pending. An unfavorable outcome could materially adversely affect financial results.
• Other Contingencies: The company faces product liability lawsuits regarding DES and Prozac, for which it has accrued estimated exposure. Environmental liabilities (Superfund) are accrued at approximately $160.9 million, with estimated insurance recoverables of $123.1 million.
• Accounting Changes: The company will adopt SFAS No. 133 (Derivatives) on January 1, 2001. Management does not expect a material effect on earnings from interest rate derivatives, though the impact on foreign currency derivatives is still being evaluated.

Investor Verification Checklist

• Verify the sustainability of the $214.4 million Kinetra gain and its impact on normalized earnings.
• Monitor the status of Prozac patent litigation appeals, specifically the Federal Circuit decision pending after March 8, 2000 oral arguments.
• Assess the rate of generic market penetration for Prozac outside the U.S. and its impact on future revenue.
• Track the execution of the new $3.0 billion share repurchase program and its effect on diluted share count.
• Review the growth trajectory of Actos and Zyprexa to confirm they offset declines in legacy products like Axid and anti-infectives.